Aurinia Pharmaceuticals Inc
NASDAQ:AUPH

Watchlist Manager
Aurinia Pharmaceuticals Inc Logo
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Watchlist
Price: 8.38 USD -1.3% Market Closed
Market Cap: 1.2B USD
Have any thoughts about
Aurinia Pharmaceuticals Inc?
Write Note

Intrinsic Value

The intrinsic value of one AUPH stock under the Base Case scenario is 11.9 USD. Compared to the current market price of 8.38 USD, Aurinia Pharmaceuticals Inc is Undervalued by 30%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AUPH Intrinsic Value
11.9 USD
Undervaluation 30%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Aurinia Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for AUPH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about AUPH?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Aurinia Pharmaceuticals Inc

Provide an overview of the primary business activities
of Aurinia Pharmaceuticals Inc.

What unique competitive advantages
does Aurinia Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Aurinia Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Aurinia Pharmaceuticals Inc recently?

Summarize the latest earnings call
of Aurinia Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Aurinia Pharmaceuticals Inc.

Provide P/S
for Aurinia Pharmaceuticals Inc.

Provide P/E
for Aurinia Pharmaceuticals Inc.

Provide P/OCF
for Aurinia Pharmaceuticals Inc.

Provide P/FCFE
for Aurinia Pharmaceuticals Inc.

Provide P/B
for Aurinia Pharmaceuticals Inc.

Provide EV/S
for Aurinia Pharmaceuticals Inc.

Provide EV/GP
for Aurinia Pharmaceuticals Inc.

Provide EV/EBITDA
for Aurinia Pharmaceuticals Inc.

Provide EV/EBIT
for Aurinia Pharmaceuticals Inc.

Provide EV/OCF
for Aurinia Pharmaceuticals Inc.

Provide EV/FCFF
for Aurinia Pharmaceuticals Inc.

Provide EV/IC
for Aurinia Pharmaceuticals Inc.

Show me price targets
for Aurinia Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Aurinia Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Aurinia Pharmaceuticals Inc?

What are the Net Income projections
for Aurinia Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Aurinia Pharmaceuticals Inc?

What are the EPS projections
for Aurinia Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Aurinia Pharmaceuticals Inc?

What are the EBIT projections
for Aurinia Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Aurinia Pharmaceuticals Inc?

Compare the revenue forecasts
for Aurinia Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Aurinia Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Aurinia Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Aurinia Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Aurinia Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Aurinia Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Aurinia Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Aurinia Pharmaceuticals Inc.

Provide ROE
for Aurinia Pharmaceuticals Inc.

Provide ROA
for Aurinia Pharmaceuticals Inc.

Provide ROIC
for Aurinia Pharmaceuticals Inc.

Provide ROCE
for Aurinia Pharmaceuticals Inc.

Provide Gross Margin
for Aurinia Pharmaceuticals Inc.

Provide Operating Margin
for Aurinia Pharmaceuticals Inc.

Provide Net Margin
for Aurinia Pharmaceuticals Inc.

Provide FCF Margin
for Aurinia Pharmaceuticals Inc.

Show all solvency ratios
for Aurinia Pharmaceuticals Inc.

Provide D/E Ratio
for Aurinia Pharmaceuticals Inc.

Provide D/A Ratio
for Aurinia Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Aurinia Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Aurinia Pharmaceuticals Inc.

Provide Quick Ratio
for Aurinia Pharmaceuticals Inc.

Provide Current Ratio
for Aurinia Pharmaceuticals Inc.

Provide Cash Ratio
for Aurinia Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Aurinia Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Aurinia Pharmaceuticals Inc?

What is the current Free Cash Flow
of Aurinia Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Aurinia Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Aurinia Pharmaceuticals Inc

Current Assets 409.7m
Cash & Short-Term Investments 330.3m
Receivables 25.5m
Other Current Assets 53.8m
Non-Current Assets 113.9m
Long-Term Investments 199k
PP&E 108.2m
Intangibles 4.6m
Other Non-Current Assets 867k
Current Liabilities 76.9m
Accounts Payable 8.4m
Accrued Liabilities 48.3m
Other Current Liabilities 20.1m
Non-Current Liabilities 82m
Long-Term Debt 64.9m
Other Non-Current Liabilities 17.1m
Efficiency

Earnings Waterfall
Aurinia Pharmaceuticals Inc

Revenue
207.1m USD
Cost of Revenue
-28.8m USD
Gross Profit
178.3m USD
Operating Expenses
-231.2m USD
Operating Income
-52.9m USD
Other Expenses
2.6m USD
Net Income
-50.4m USD

Free Cash Flow Analysis
Aurinia Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

AUPH Profitability Score
Profitability Due Diligence

Aurinia Pharmaceuticals Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

35/100
Profitability
Score

Aurinia Pharmaceuticals Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

AUPH Solvency Score
Solvency Due Diligence

Aurinia Pharmaceuticals Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
67/100
Solvency
Score

Aurinia Pharmaceuticals Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AUPH Price Targets Summary
Aurinia Pharmaceuticals Inc

Wall Street analysts forecast AUPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AUPH is 9.97 USD with a low forecast of 6.06 USD and a high forecast of 13.65 USD.

Lowest
Price Target
6.06 USD
28% Downside
Average
Price Target
9.97 USD
19% Upside
Highest
Price Target
13.65 USD
63% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AUPH?

Click here to dive deeper.

Dividends

Aurinia Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for AUPH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

AUPH Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

AUPH News

Profile

Aurinia Pharmaceuticals Inc Logo
Aurinia Pharmaceuticals Inc

Country

Canada

Industry

Biotechnology

Market Cap

1.2B USD

Dividend Yield

0%

Description

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company is headquartered in Victoria, British Columbia and currently employs 300 full-time employees. The company went IPO on 2001-07-16. The firm is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The firm has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. The company also focuses on treatment of autoimmune, fibrotic, and kidney-related diseases. Its product pipeline includes AUR200, AUR300.

Contact

BRITISH COLUMBIA
Victoria
1203-4464 Markham St
+12507084272.0
www.auriniapharma.com

IPO

2001-07-16

Employees

300

Officers

Chief Financial Officer
Mr. Joseph M. Miller CPA
Head of the Corporate Communications & Investor Relations
Ms. Andrea Levin Christopher
Chief Business Officer
Mr. Michael R. Martin
Senior Vice President of Global Regulatory Affairs
Ms. Sue Evans
Chief Commercial Officer
Mr. Scott Habig
Chief Medical Officer
Dr. Gregory F. Keenan M.D.
Show More
Senior Vice President of Quality
Dr. Ann M. Daus Ph.D.
Senior Vice President of Manufacturing & Supply Chain
Dr. Premchandran Ramiya Ph.D.
Vice President of Investor Relation
Ms. DeDe Sheel
Show Less

See Also

Discover More
What is the Intrinsic Value of one AUPH stock?

The intrinsic value of one AUPH stock under the Base Case scenario is 11.9 USD.

Is AUPH stock undervalued or overvalued?

Compared to the current market price of 8.38 USD, Aurinia Pharmaceuticals Inc is Undervalued by 30%.

Back to Top